Summary: Triptan, a drug that is usually prescribed for migraine relief, can be effective in treating obesity. Daily exposure to tetanus has reduced food intake and increased weight loss in mice models.

Source: UT Southwest

Tripletans, a common form of migraine, may be useful in treating obesity, according to a new study by UT Southwest scientists.

In a study of obese mice, a daily dose of tryptan helped animals eat less food and lose weight within a month, the team reported. Journal of Experimental Medicine.

“We have shown that these drugs have the potential to suppress already known appetite and weight loss,” said lead researcher Chen Liu, PhD, assistant professor of internal medicine and neuroscience and researcher at the Peter Odonel Junior Brain Institute.

Obesity affects more than 41% of adults in the US and increases their risk of heart disease, stroke, diabetes and certain types of cancer. Most obesity treatments focus on diet and exercise.

Scientists have long known that serotonin, a chemical in the brain and body, plays a key role in appetite. However, there are 15 different serotonin receptors – molecules and cells that know serotonin signal to change their behavior in response.

Researchers have struggled to understand the role of each serotonin receptor in appetite, and side effects of specific drugs – including fen-phen and lorcaserin (Belviq) – have been removed from the market.

Triptans, which are used to treat acute migraine and cluster headaches, have not been studied in a particular way – serotonin 1B receptor (Htr1b) – in terms of appetite and weight loss, Dr. Liu said.

For the new study, the researchers tested six prescription drugs in obese mice for seven weeks. Two of these rats ate the same amount, while the other four ate less.

After 24 days, rats treated with progesterone daily lost an average of 3.6%, while non-tryptan mice gained an average of 5.1%. Dr. Liu and his colleagues have seen similar results when they implanted animals in a continuous supply of fluoxetine for 24 days.

“We know that these drugs, in particular, can help you lose weight and improve your glucose metabolism in less than a month,” said Dr. Liu.

This is shown by a woman measuring her waist.
Obesity affects more than 41% of adults in the US and increases their risk of heart disease, stroke, diabetes and certain types of cancer. Image is in the public domain.

Because Triptan is generally prescribed for short-term use during migraines, Dr. Liu suspects that patients have not noticed long-term effects on appetite and weight.

To determine the exact effect of frovatriptan on food intake and weight, researchers prevented mice from having Htr1b or Htr2c targeting fen-phen and lorcaserin. In mice without Htr1b, provotaptan may not reduce appetite or weight loss, but discontinuing Htr2c has no effect. This confirms that the drug works by targeting the serotonin 1B receptor.

“This discovery could be useful for drug development,” said Dr. Liu. “We have focused on the Htr1b candidate to not only shed light on its potential to reuse existing Triptan, but also to treat obesity and control food intake.”

The group showed HTR 1B in a small group of cells in the hypothalamus of the brain that played a key role in regulating appetite.

Other researchers who contributed to the study were Lee Lee, Steven C. Willer, Louis A. Leon-Mercado, Baiji Shu, Swati, Xiaming Chen, Rong Wan, and Amanda G. Arnold of UT Southwest. Eugene O. and Jong-soo Son of Korea Institute of Advanced Science and Technology; UT Dallas Lynn Jia; Oxford University Guanlin Wang; Katherine Nautral, Darthmus College; And Renee Hein Columbia University.

Financial support The study was funded by the National Institutes of Health (R01 DK114036, DK130892, F32DK116427, K01AA024809), the American Health Association (16SDG27260001), the UTSW Pilot and Practice Award, and the Grossman Endowment Excellence Research Award.

watch out

This shows a group of kindergarten children

Hence the news of neuropharmacology and weight loss research

Author Press Office
Source: UT Southwest
Contact Press Office – UT Southwest
Image The image is in the public domain.

Preliminary study Closed access.
Identification of serotonin 1B receptor circuit to suppress appetite in rats”By Chen Liu et al. Journal of Experimental Medicine


Identification of serotonin 1B receptor circuit to suppress appetite in rats

Triptans are part of the most commonly prescribed anti-migraine medication. Here, we report a previously unrecognized role in suppressing appetite in mice. In particular, prophylactic treatment reduces dietary intake and weight gain in obese rats due to diet.

Moreover, the anorexic effect depends on the serotonin (5-HT) 1B receptor.Htr1b). By uninstalling Htr1b In four different brain regions, we show that Htr1b It is involved in specialized neurotransmitter pathways in spatial growth to control postpartum growth and food intake.

Moreover, Htr1b In the AgRP nerves in the hypothalamus (ARH) arcuate nucleus contributes to the hypophagic effect of HTR1B agonists. We created the anorexigenic Htr1b circuit to further study Htr1b-Cre Rats.

We get that ARH Htr1b Nerve cells control food intake in vivo in two directions. In addition, a series of single-nucleus RNA analyzes showed that. Htr1b Refers to a subset of AGR neurons. Finally, we used a termination method to target these neurons (Htr1b.).AgRP Nerve cells).

We show that you partially control food through Htr1b.AgRPቪ PVH District.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *